The absence of a molecular target (i.e., ER-negative, PR-negative, and HER2-negative) is regarded as a triple-negative (TN) breast cancer subtype that indicates a worse prognosis for the patient [5]. This evidence concerns the gene ESR1 and breast carcinoma.